Category

Archives

PD-1/PD-L1

Ivacaftor-elexacaftor-tezacaftor and tacrolimus combination in cystic fibrosis

6 views | Jun 21 2021

Megan Smith et al. described a pediatric liver transplant recipient with clinical decline related to cystic fibrosis who improved substantially with ETI, without significant impact on the systemic exposure of either ETI or tacrolimus. [Read the Full Post]

Synthesis and Evaluation of Biphenyl-1,2,3-Triazol-Benzonitrile Derivatives as PD-1/PD-L1 Inhibitors

14 views | Apr 23 2021

Suresh Narva et al. thought that compound 7 was thus a promising candidate for further optimization as an inhibitor of the PD-1/PD-L1 signaling pathway. [Read the Full Post]

Mnk inhibitors: a patent review

29 views | Mar 07 2021

Ahmed M Abdelaziz et al. provided a succinct review of the current state of development of pyridone-aminal-derived Mnk inhibitors through the analysis of relevant patent applications filed in the last 5 years. [Read the Full Post]

Novel miRNAs as Potential Regulators of PD-1/PD-L1 Immune Checkpoint, and Prognostic Value of MIR9-1 and MIR124-2 Methylation in Ovarian Cancer

39 views | Dec 05 2020

N E Kushlinskii et al. suggested the role of inhibitors of the sPD-L1 immune checkpoint for five miRNAs (miR-124, miR-34b, miR-34c, miR-9, miR-339) and the possibility of using hypermethylated MIR9-1. [Read the Full Post]